ID: ALA5182301

Max Phase: Preclinical

Molecular Formula: C23H23N3O

Molecular Weight: 357.46

Representations

Canonical SMILES:  N#Cc1ccc(-c2ccc3c(ccc(=O)n3CCN3CCCCC3)c2)cc1

Standard InChI:  InChI=1S/C23H23N3O/c24-17-18-4-6-19(7-5-18)20-8-10-22-21(16-20)9-11-23(27)26(22)15-14-25-12-2-1-3-13-25/h4-11,16H,1-3,12-15H2

Standard InChI Key:  DHPIMHFFFCMLQJ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 357.46

Molecular Weight (Monoisotopic): 357.1841

AlogP: 4.03

#Rotatable Bonds: 4

Polar Surface Area: 49.03

Molecular Species: NEUTRAL

HBA: 4

HBD: 0

#RO5 Violations: 0

HBA (Lipinski): 4

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 0

CX Acidic pKa:

CX Basic pKa: 8.14

CX LogP: 3.83

CX LogD: 3.02

Aromatic Rings: 3

Heavy Atoms: 27

QED Weighted: 0.71

Np Likeness Score: -1.23

References

1. Patel MV, Peltier HM, Matulenko MA, Koenig JR, C Scanio MJ, Gum RJ, El-Kouhen OF, Fricano MM, Lundgaard GL, Neelands T, Zhang XF, Zhan C, Pai M, Ghoreishi-Haack N, Hudzik T, Gintant G, Martin R, McGaraughty S, Xu J, Bow D, Kalvass JC, Kym PR, DeGoey DA, Kort ME..  (2022)  Discovery of (R)-(3-fluoropyrrolidin-1-yl)(6-((5-(trifluoromethyl)pyridin-2-yl)oxy)quinolin-2-yl)methanone (ABBV-318) and analogs as small molecule Na_v1.7/ Nav1.8 blockers for the treatment of pain.,  63  [PMID:35436748] [10.1016/j.bmc.2022.116743]

Source

Source(1):

• Scientific Literature